Agilent announces new ProteoAnalyzer system

Automated parallel capillary electrophoresis system simplifies protein analysis

Parexel collaborates with Japanese Foundation for cancer research

Collaboration streamlines patient access to oncology clinical trials

Lupin Life hosted Second Edition of Aptivate Champion Run for Kids

The Aptivate Champion Run witnessed an enthusiastic participation of over 4,000 Mumbaikars

Lupin receives USFDA’s approval or Propranolol Hydrochloride Extended-Release Capsules USP

ARTBIO and PharmaLogic inks supply agreement for Lead-212 based Therapeutic Candidate for treatment of prostate cancer

PharmaLogic will assist ARTBIO with radiochemistry and supply of the finished radiopharmaceutical product for future Phase I and II clinical trials of AB001 from their facility in New York

USFDA approves Merck’s Keytruda plus chemoradiotherapy with FIGO 2014 stage III-IVA cervical cancer

Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients

Shanghai Argo announces multi-program RNAi licenses with Novartis

Argo will receive upfront payments of US$ 185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales.

SyntheticGestalt collaborates with Enamine to create AI-based model to facilitate drug discovery

SyntheticGestalt will develop a pre-trained AI model to discover synthesizable drug-like hit candidates

USFDA accepts sBLA of TIVDAK for priority review for patients with metastatic cervical cancer

Submission based on positive results from global phase 3 study demonstrating overall survival benefit of TIVDAK over chemotherapy

Merck to acquire Harpoon Therapeutics for US$ 680 million

Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors